In brief, the presented results show that refractory AML patients demonstrate significantly higher oncogenic MYC and WT1, metabolic IDH1 and pro-apoptotic DAPK1 gene expression and significantly lower cell-cycle-inhibitor CDKN1A (p21) gene expression both at diagnosis and after clinical treatment. This evidence concerns the gene IDH1 and acute myeloid leukemia.